Physician profile
Li Yang
NPI 1598035081
$19,002.54
in general payments reported to CMS, 2019-2025
36 companies · $2,639 in 2025
The $2,639 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $678 · 2021: $1,703 · 2022: $2,030 · 2023: $2,359 · 2024: $8,105 · 2025: $2,639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,392 · Consulting Fee: $5,225 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,392.31 |
| Consulting Fee | $5,225.00 |
| Education | $485.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $6,086.89 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $1,378.24 | 2019-2025 | Lokelma, Farxiga |
| Esperion Therapeutics, INC. | $1,078.66 | 2020-2025 | Nexletol |
| Amgen INC. | $996.84 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $959.54 | 2020-2025 | Benlysta, Jesduvroq |
| Opko Pharmaceuticals, LLC | $912.64 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $865.35 | 2019-2025 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $828.97 | 2020-2025 | Filspari |
| Fresenius USA Marketing, INC. | $674.75 | 2019-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $648.26 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $488.90 | 2019-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $456.03 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $431.08 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $396.60 | 2023-2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $380.53 | 2020-2024 | Acthar |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $375.02 | 2019-2022 | |
| Ardelyx, INC. | $356.33 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $322.39 | 2019-2025 | |
| Horizon Therapeutics Plc | $256.16 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $145.06 | 2021-2025 | Lupkynis |
| Sumitomo Pharma America, INC. | $129.67 | 2024-2025 | Gemtesa |
| Lexicon Pharmaceuticals, INC. | $124.99 | 2024 | Inpefa |
| Phathom Pharmaceuticals, INC. | $103.10 | 2024 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.66 | 2019-2025 | Voyxact |
| Regeneron Healthcare Solutions, INC. | $95.14 | 2019 | |
| Allergan, INC. | $79.27 | 2019-2020 | |
| Gilead Sciences, INC. | $66.77 | 2022 | |
| Nestle Healthcare Nutrition INC. | $60.07 | 2021-2023 | |
| Novo Nordisk INC | $53.28 | 2020 | |
| Merck Sharp & Dohme LLC | $44.26 | 2023-2025 | Verquvo |
| Lilly USA, LLC | $22.18 | 2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $19.44 | 2019 | |
| Shire North American Group INC | $17.87 | 2019 | |
| Shield Therapeutics INC | $17.49 | 2025 | |
| Ibsa Pharma INC. | $15.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.